Table 13.
Patient-reported outcome results for all therapies of interest
| Study/N/Age/Location | Intervention and treatment duration | Outcomes | Summary |
|---|---|---|---|
| Comparing different settings for administration of IVMP | |||
| Chataway, Porter, Riazi, Heaney, Watt, Hobart, Thompson31 N=138 Mean age, years: outpatient treatment: 40.4; home treatment: 36.8 UK |
Intervention IVMP outpatient setting (n=69) vs IVMP home setting (n=69) Treatment duration 3 days Assessments Baseline and 6 weeks later |
SF−36 score improvement at week 6: Physical score change: outpatient, 7.7; home, 17.4; P=0.116 Emotional score change: outpatient, 1.3; home, 10.6; P=0.270 Pain score change: outpatient, 8.8; home, 12.2; P=0.420 Energy and Vitality score change: outpatient, 8.4; home, −9.4In contrast to all of the other values presented here, this result signifies a reduction in QOL.a; P=0.767 General Health Perceptions score change: outpatient, 4.7; home, 1.0; P=0.238 Social Functioning score change: outpatient, 16.2; home, 11.0; P=0.298 Physical Functioning score change: outpatient, 6.4; home, 8.8; P=0.493 Mental Health score change: outpatient, 5.8; home, 7.4; P=0.599 |
Both outpatient and home treatment groups showed an improvement in SF-36 after 6 weeks of treatment |
| Craig, Young, Ennis, Baker, Boggild49 N=40 Mean age at entry, years: treatment: 38; control: 42 UK |
Intervention IVMP with planned, comprehensive multidisciplinary team care (treatment)(n=20) vs IVMP with standard care (control)(n=20) Treatment duration 3 days Assessments Admission, 1 month and 3 months after day 1 of treatment onset |
SF-36 mean score change at 1 month: Physical Function: treatment, 15.2; control, 13 Social Function: treatment, 29.5; control, 27.4 Role Physical: treatment, 33.7; control, 8.8 Role Emotional: treatment, 33.3; control, 20.0 Mental Health: treatment, 14.6; control, 10.6 Energy: treatment, 22.2; control, 0.6 Pain: treatment, 18.0; control, 21.0 General Health: treatment, 11.8; control, 0.40 SF-36 mean score change at 3 months: Physical Function: treatment, 22.0; control, 9.25 Social Function: treatment, 34.1; control, 15.2 Role Physical: treatment, 30.0; control, 16.25 Role Emotional: treatment, 00.0; control, −10.0 Mental Health: treatment, 19.35; control, 5.7 Energy: treatment, 19.00; control, 9.00 Pain: treatment, 11.3; control, 7.15 General Health: treatment, 8.95; control, −1.4 |
Clinically significant change score (≥10) in all 8 domains in the treatment group at 1 month was established, and in 6 of the 8 domains (except Role Emotional and General Health domains) in the treatment group. |
| IVMP vs OMP | |||
| Ramo-Tello et al (2014);34 Grau-Lopez et al (2014)39 N=49 Mean age, years: IVMP, 37.7; OMP, 39.5 Spain |
Intervention IVMP (n=24) OMP (n=25) Treatment duration IVMP and OMP: 3 days Assessments Baseline, weeks 1, 4, and 12 |
MusiQoL score: time of relapse, 62.8; 4 weeks, 71.5 (P=0.05) MusiQoL had lower scores at the time of relapse than at 4 weeks after MP treatment (62.8 vs 71.5; P=0.05). MusiQoL score showed no differences between patients with higher or lower relapse severity at any point analyzed (t=0, 62.2 vs 63.1; week 1, 64.4 vs 64.1; week 4, 71.1 vs 72.8). A positive correlation was found between MusiQoL scores and baseline disability (R=0.37; P=0.02). |
QOL increased 4 weeks after relapse. Patients with greater disability had worse QOL regardless of the intensity of relapse. |
Note: aIn contrast to all of the other values presented here, this result signifies a reduction in QOL.
Abbreviations: EDSS, Expanded Disability Status Scale; IVMP, intravenous methylprednisolone; MSIS-29, Multiple Sclerosis Impact Scale; MSWS-12= Multiple Sclerosis Walking Scale; MusiQoL, Multiple Sclerosis International Quality of Life questionnaire; OMP, oral methylprednisolone; QOL, quality of life; SF-36, SF-36 Health Survey; UK, United Kingdom; US, United States.